Adjuvant Dual HER2-Targeted Therapy for HER2+ Early-Stage Breast Cancer

September 15, 2017

Adjuvant Dual HER2-Targeted Therapy for HER2+ Early-Stage Breast Cancer


  • A 49-year-old women was referred for biopsy after routine mammography showed a 2.4-cm diameter spiculated mass in the left breast
  • PE: revealed a well-circumscribed, non-tender firm mass in the lower-outer quadrant of the left breast; singular palpable nodal enlargement in the left axilla
  • Excisional biopsy of the breast and axillary lymph nodes showed high grade lobular carcinoma
    • ER-/PR-; HER2 IHC 3+; Ki-67, 89%
    • Staging, pT2N3M0
  • She underwent right mastectomy and lymph node dissection
  • The patient was started on adjuvant chemotherapy with docetaxel + carboplatin with 12 months of trastuzumab + pertuzumab